155 related articles for article (PubMed ID: 27402583)
21. Trends in Hospital Visits for Generic and Brand-Name Warfarin Users in Québec, Canada: A Population-Based Time Series Analysis.
Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
Am J Cardiovasc Drugs; 2019 Jun; 19(3):287-297. PubMed ID: 30471054
[TBL] [Abstract][Full Text] [Related]
22. A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials.
Yu Y; Teerenstra S; Neef C; Burger D; Maliepaard M
Br J Clin Pharmacol; 2016 Apr; 81(4):667-78. PubMed ID: 26574160
[TBL] [Abstract][Full Text] [Related]
23. Nonpublication Rates and Characteristics of Registered Randomized Clinical Trials in Digital Health: Cross-Sectional Analysis.
Al-Durra M; Nolan RP; Seto E; Cafazzo JA; Eysenbach G
J Med Internet Res; 2018 Dec; 20(12):e11924. PubMed ID: 30485832
[TBL] [Abstract][Full Text] [Related]
24. Are generic drugs really inferior medicines?
Moore N; Berdaï D; Bégaud B
Clin Pharmacol Ther; 2010 Sep; 88(3):302-4. PubMed ID: 20725079
[TBL] [Abstract][Full Text] [Related]
25. Searches for randomized controlled trials of drugs in MEDLINE and EMBASE using only generic drug names compared with searches applied in current practice in systematic reviews.
Waffenschmidt S; Guddat C
Res Synth Methods; 2015 Jun; 6(2):188-94. PubMed ID: 26099486
[TBL] [Abstract][Full Text] [Related]
26. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
Contin M; Alberghini L; Candela C; Benini G; Riva R
Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080
[TBL] [Abstract][Full Text] [Related]
27. Factors influencing consumer purchasing patterns of generic versus brand name over-the-counter drugs.
Kohli E; Buller A
South Med J; 2013 Feb; 106(2):155-60. PubMed ID: 23380752
[TBL] [Abstract][Full Text] [Related]
28. Converting patients from brand-name clozapine to generic clozapine.
Sajbel TA; Carter GW; Wiley RB
Ann Pharmacother; 2001 Mar; 35(3):281-4. PubMed ID: 11261523
[TBL] [Abstract][Full Text] [Related]
29. [Bioequivalence and generics of index drugs with narrow therapeutic margins].
Le Corre P
Presse Med; 2010 Feb; 39(2):169-76. PubMed ID: 19932591
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation.
Ochi N; Yamane H; Hotta K; Fujii H; Isozaki H; Honda Y; Yamagishi T; Kubo T; Tanimoto M; Kiura K; Takigawa N
Drug Des Devel Ther; 2014; 8():2401-8. PubMed ID: 25584019
[TBL] [Abstract][Full Text] [Related]
31. Generic versus brand-name North American topical glaucoma drops.
Mammo ZN; Flanagan JG; James DF; Trope GE
Can J Ophthalmol; 2012 Feb; 47(1):55-61. PubMed ID: 22333853
[TBL] [Abstract][Full Text] [Related]
32. Comparison of noninferiority margins reported in protocols and publications showed incomplete and inconsistent reporting.
Dekkers OM; Cevallos M; Bührer J; Poncet A; Ackermann Rau S; Perneger TV; Egger M
J Clin Epidemiol; 2015 May; 68(5):510-7. PubMed ID: 25450451
[TBL] [Abstract][Full Text] [Related]
33. Trial registry searches for randomized controlled trials of new drugs required registry-specific adaptation to achieve adequate sensitivity.
Knelangen M; Hausner E; Metzendorf MI; Sturtz S; Waffenschmidt S
J Clin Epidemiol; 2018 Feb; 94():69-75. PubMed ID: 29132833
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic equivalency of generic antiepileptic drugs: results of a survey.
Wilner AN
Epilepsy Behav; 2004 Dec; 5(6):995-8. PubMed ID: 15582850
[TBL] [Abstract][Full Text] [Related]
35. Is bioavailability altered in generic versus brand anticonvulsants?
Jankovic SM; Ignjatovic Ristic D
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):329-32. PubMed ID: 25440299
[TBL] [Abstract][Full Text] [Related]
36. Changing understanding, perceptions, pain relief of and preference for generic medicines with patient education: An experimental intervention study.
Kleinstäuber M; Colgan S; Petrie KJ
Res Social Adm Pharm; 2021 Jul; 17(7):1288-1299. PubMed ID: 33012643
[TBL] [Abstract][Full Text] [Related]
37. Are Generic Drugs Used in Cardiology as Effective and Safe as their Brand-name Counterparts? A Systematic Review and Meta-analysis.
Leclerc J; Thibault M; Midiani Gonella J; Beaudoin C; Sampalis J
Drugs; 2020 May; 80(7):697-710. PubMed ID: 32279239
[TBL] [Abstract][Full Text] [Related]
38. Investigation of Bioequivalence Between Brand-name and Generic Irinotecan Products.
Saito KI; Inoue Y; Ikegami Y; Nanbo I; Onozuka M; Sano K; Yoshida H; Sakamoto T; Tatebayashi E; Fujita KI; Sasaki Y; Kitazawa T
Anticancer Res; 2016 Nov; 36(11):5957-5963. PubMed ID: 27793921
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials of Orthopaedic Surgical Interventions.
Rongen JJ; Hannink G
J Bone Joint Surg Am; 2016 Mar; 98(5):403-9. PubMed ID: 26935463
[TBL] [Abstract][Full Text] [Related]
40. Generic drugs in dermatology: part II.
Payette M; Grant-Kels JM
J Am Acad Dermatol; 2012 Mar; 66(3):353.e1-15; quiz 367-8. PubMed ID: 22342022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
